Towards Healthcare
Sequencing Market (22.21% Healthy CAGR) | Companies Report

Sequencing Market Size (USD 115.85 Bn by 2033) Report

The report covers Sequencing Market Trends and Manufacturers such as BGI, PacBio, Eurofins GATC Biotech GmbH, Perkin Elmer, Inc., DNASTAR, Inc., Genomatix GmbH, PierianDx, Oxford Nanopore Technologies, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., QIAGEN, F. Hoffman-La Roche Ltd. and Illumina, Inc. The report offers the value (in USD Billion) for the above segments.

Sequencing Market Size, Growth and Future Analysis Report

The global sequencing market size was estimated at US$ 15.59 billion in 2023 and is projected to grow US$ 115.85 billion by 2033, rising at a compound annual growth rate (CAGR) of 22.21% from 2024 to 2033. The market is witnessing rapid growth due to increased applications in different industries.

Sequencing Market Revenue 2023 - 2033

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways

  • North America dominated the market with the largest revenue share of 50% in 2023.
  • Asia Pacific is expected to witness the fastest growth during the forecast period.
  • By product & service, the consumables segment has contributed more than 45% of revenue share in 2023.
  • By workflow, the sequencing segment dominated the market with the largest revenue share of 57% in 2023.
  • By workflow, the data analysis segment is expected to witness the fastest growth during the forecast period.
  • By application, the oncology segment has recorded more than 29% of revenue share in 2023.
  • By application, the consumer genomics segment is expected to witness the fastest growth during the forecast period.

Industry at a Glance

The sequencing market encompasses all the resources, including reagents & kits, equipment, evidence, professionals, etc, for sequencing of DNA, RNA, and protein. In the sequencing process, the sequence of nucleotides in DNA and RNA and the sequence of amino acids in a protein are determined with the help of different tools and techniques. With the use of sequencing data, scientists can find variations in genes and noncoding DNA (such as regulatory sequences), correlations with phenotypes and illnesses, and possible targets for future medications. Numerous fields, including the study of diseases, developmental biology, epigenetics, evolution, genetic relationships between various species, the creation of genetically engineered organisms and vaccines, and disease research, have benefited greatly from sequencing. The sequencing market has a lot of room to develop in the future because of rising technology, rising food consumption and rising healthcare sector demand brought on by the rising incidence of chronic illnesses.

Top Companies in the Sequencing Market

  • BGI
  • PacBio
  • Eurofins GATC Biotech GmbH
  • Perkin Elmer, Inc.
  • DNASTAR, Inc.
  • Genomatix GmbH
  • PierianDx
  • Oxford Nanopore Technologies
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN
  • F. Hoffman-La Roche Ltd.
  • Illumina, Inc.

Illumina Inc. Pipeline in the Sequencing Market

Company Name Illumina Inc.
Headquarters California, U.S.
Pipeline A fast, repeatable, and scalable whole-genome sequencing process in 2024. In order to increase speed, reproducibility, and scalability to provide rWGS of 13.5 hours, Illumina is studying and developing a new, reengineered genome sequencing methodology. With the help of Illumina's next-generation sequencing (NGS) technology, this pipeline—which was created in partnership with Rady Children's Institute for Genomic Medicine—eliminates crucial bottlenecks in traditional rWGS workflows by streamlining variant calling, sequencing, and library preparation for quick and precise identification of genetic variants, including complex structural variation.

PacBio Pipeline in the Sequencing Market

Company Name PacBio
Headquarters California, U.S.
Pipeline In October 2023, PacBio WGS Variant Pipeline, a full, standardized computational technique for HiFi whole genome sequencing (WGS) data interpretation, was made available. PacBio is a leading producer of high-quality, highly accurate sequencing products. Customers will be able to resolve a wide variety of variant types using the new software pipeline, which makes it the most comprehensive human WGS secondary analysis process out there.

The Growing Demand for Gene Therapy is Driving the Sequencing Market

Because there are more and more genetic problems, gene therapy is one of the medical specialties that is expanding the quickest. Gene therapies are a promising class of treatments that can be used to treat a wide range of diseases; their goal is to treat the underlying causes of the diseases rather than just their symptoms. Numerous illnesses that were previously incurable, including cancer and neurological and hematological disorders, may respond well to them. Gene treatments are thought to have the potential to revolutionize the pharmaceutical and health sciences. Globally, there are more and more clinical studies looking at gene therapy.

For instance,

  • According to epidemiologic research, 2–6% of people worldwide suffer from a rare disease, with up to 80% of cases having a hereditary basis. The growing body of data demonstrating that genome sequencing (GS) can stop the so-called diagnostic odyssey for as many as 20–60% of newborns and 17–40% of juvenile patients with a suspected genetic illness highlights the diagnostic potential of GS4. Studies indicate that up to 77% of patients experience a change in care as a result of getting diagnostic genome findings, indicating that GS testing frequently results in quantifiable changes in management.

Ethical Concerns Regarding Genetic Data Restraint the Sequencing Market’s Growth

Traditional notions of informed consent are called into question, and privacy and security concerns are heightened by the growing collection and use of private medical and biological data, such as that needed for genomics research. Importantly, new problems will come up since a big and diversified collection of genetic information is necessary for an efficient genomic service. There may be worries expressed about the possibility of major privacy violations from unintentional data releases or illegal activities like hacking or data theft. Without an express agreement, it is morally acceptable to regularly collect, store, and connect genetic data to be kept in healthcare service records. Authorized access to data should also be promoted.

Integration of Artificial Intelligence and Machine Learning Hold Great Potential for Growth

Advanced computing and inference techniques used by AI give insights that improve medical decision-making by allowing the system to reason and learn. Cell properties that may be evaluated at high throughput and utilized as training targets for predictive models include splicing, protein binding to nucleic acids and gene up-regulation. The enhanced accessibility of a wide range of information and contemporary computer methods like machine learning can help researchers usher in a new era of efficient genomic medicine.

For instance,

  • In April 2024, a data portal was developed by a nonprofit medical research foundation with the aim of promoting scientific advancements in the field of amyotrophic lateral sclerosis (ALS). According to Target ALS, the new site will offer unrestricted access to extensive datasets and analytical tools to accelerate the search for ALS treatments and biomarkers. The Omics artificial intelligence (AI) software package from Canadian startup DNAstack powers the data portal, which makes use of Verily Workbench to provide safe access to and analysis of multimodal ALS data.

Report Highlights

Product Insights

By product & service, the consumables segment dominated the sequencing market in 2023. From straightforward procedures and materials for DNA cloning, molecular biology kits have developed into more sophisticated sets of reagents that allow for whole genome sequencing. These days, kits may be obtained anywhere—from the home medicine cabinet to the doctor's office. They are no longer limited to the lab. The offspring of lab kits from bygone eras, as well as over-the-counter home tests, come in various forms, including DNA testing. Even now, the reagents and kits are showing up online. Additionally, kits for RNAi, quantitative PCR, rapid PCR, long-range PCR, genotyping, and other techniques that expedite research or simplify lab life are in great demand. These days, kits constitute a crucial component of many biological instruments.

For instance,

  • In May 2024, the QIAseq Multimodal DNA/RNA Lib Kit was launched, according to QIAGEN. With the help of this new kit, next-generation sequencing (NGS) projects like whole transcriptome sequencing (WTS) and whole genome sequencing (WGS) may be prepared with ease. It also makes it possible to enrich targets downstream using hybrid capture from a single sample. The goal of multi-omics, or the study of many omic disciplines such as transcriptomics, proteomics, and genomics, is to better understand biological systems and processes. The QIAseq Multimodal DNA/RNA Lib Kit makes this possible.

Workflow Insights

By workflow, the sequencing segment dominated the sequencing market in 2023. Throughout the previous 20 years, there has been a noticeable advancement in genome sequencing technology in terms of cost and time. Now, a new single-molecule sequencing method called third-generation sequencing is being developed. These strategies have been developed to lower sequencing costs and automate preprocessing and sequencing operations. Exciting developments and new findings in a variety of academic domains will be provided by sequencing in the future. Improvements to diagnostic techniques are made possible by the steady rise of sequencing technology. Enhancing productivity and accuracy while cutting down on processing time will be the future objectives of researchers. Scientists utilize the information gathered from sequencing to create novel prognostic and diagnostic approaches.

For instance,

  • In April 2024, launching its next-generation sequencing (NGS) and optical mapping platform, NewBiologix SA, a technology innovation company focused on filling gaps in gene therapy manufacturing, announced the combination of these innovative technologies to provide the biopharmaceutical industry with a comprehensive suite of genomic analysis services. This platform combines the most recent developments in sequencing and genomic mapping technology by merging the capabilities of leading companies in the field, including Illumina, PacBio, Nanopore, and Bionano. A flexible framework that can handle the intricate requirements of genomic research is the end product.

By workflow, the data analysis segment is expected to witness the fastest growth during the forecast period. Large amounts of data are produced by sequencing, and the necessary analysis might be frightening. Thankfully, the majority of the manual labor involved in the NGS data processing process is eliminated by the analytical tools that are already on the market, making it simpler for you to obtain important information quickly. Primary, secondary, and tertiary data analysis are the three key processes in the NGS data analysis process. Certain actions are carried out automatically by the sequencing device, and other actions take place once the sequencing process is finished. An important phase in biological research that involves processing and interpreting large amounts of data obtained from biological specimens is known as genomic data analysis.

For instance,

  • In May 2024, pioneers in genomic research and technology, BioAro, officially introduced PanOmiQ, a game-changing piece of software that will revolutionize genomic analysis worldwide by giving real-time insights into the intricate workings of the human genome. With unmatched speed, accuracy, and adaptability, it is poised to revolutionize healthcare around the globe. On May 9, 2024, in the Dubai World Trade Center in the United Arab Emirates, the PanOmiQ software was introduced to the world at the Precision Medicine Expo.

Application Insights

By application, the oncology segment dominated the sequencing market in 2023. The development, control, and progression of cancer have become better understood because of NGS-based cancer sequencing techniques, which have also opened up new research avenues. These methods aid in the identification of genomic alterations in cancer and their effects on the transcriptome, epigenome, and proteome. NGS significantly increases the possibility of the discovery of each sample by evaluating hundreds of targets simultaneously. Additionally, low-frequency molecular events linked to cancer development, metastasis, and carcinogenesis that may go undetected by conventional molecular techniques can be found by NGS. When taken as a whole, these developments are opening the door to better translational medicine and therapeutics in the future. With the growing prevalence of cases of cancer, the need for sequencing will grow continuously.

For instance,

  • More than 35 million new cases of cancer are expected in 2050, which is a 77% increase over the 20 million cases expected in 2022. In 2022, there were 20 million new cases of cancer and 9.7 million cancer-related deaths. It was estimated that 53.5 million individuals would still be living five years after being diagnosed with cancer. One in five people will experience cancer at some time in their life. Lung cancer is the most common cancer, accounting for 2.5 million new cases worldwide, or 12.4% of all new cases. Prostate cancer (1.5 million cases, 7.3%), stomach cancer (970,000 cases, 4.9%), colon cancer (1.9 million cases, 9.6%), and female breast cancer (2.3 million cases, 11.6%) were the next in incidence order.

By application, the consumer genomics segment is expected to witness the fastest growth during the forecast period. By 2022, it is expected to have increased by a factor of ten, reaching up to 100 million genotyped people. The growth rate is probably going to outpace these estimates due to lower costs associated with genotyping and sequencing as well as more promotional expenditure from industry leaders. More businesses will join the genomics direct-to-consumer (retail) industry in the upcoming years. Greater innovation and insight will be possible as a result of the large returns on scale that these enormous numbers of genotyped customers will produce. Large sample numbers provide increased statistical power to identify connections across the genome, which might be helpful in establishing a connection between functional qualities, clinical symptoms, and genetic markers.

Regional Insights

By region, North America dominated the sequencing market in 2023 due to the leading industry competitors' continuous technical developments. The region's genome sequencing market is expected to rise due in part to the substantial investments made in research and development as well as the high accessibility of scientifically established healthcare infrastructure. The countries that majorly contribute to the market growth in the region are the U.S. and Canada.

The AMD initiative hires bioinformatics experts, trains public health personnel in the U.S., and deploys next-generation sequencing tools at the CDC and in state and local health agencies. The AMD program contributes to the development and integration of epidemiology, bioinformatics, and laboratory technologies inside the CDC as well as in state and local public health systems. In order to create and test next-generation diagnostics and procedures with and for the CDC as well as state, municipal, and public health laboratories, the AMD program supports other initiatives within the agency.

For instance,

  • In May 2024, the RNA sequencing test FoundationOne RNA, developed by Boston-based Foundation Medicine, is now available for purchase in the U.S.. An individual RNA molecule has the potential to identify fusions inside solid tumors and may potentially be employed in various types of cancer including pancreatic, thyroid, bladder, cholangiocarcinoma, sarcoma, and non-small cell lung cancer (NSCLC).

By region, Asia Pacific is expected to witness the fastest growth during the forecast period. The sequencing market is anticipated to be driven by the existence of regional businesses like BGI Genomics and NGS service providers like First BASE Laboratories Sdn Bhd, Macrogen Asia-Pacific Pte Ltd., and others. Countries like India, China, Japan, and South Korea contribute to the growth.

There are about 4,600 different demographic groupings in India, home to 1.3 billion people, many of whom practice endogamy. The current population's genetic diversity is a result of these influences. As a result, there are many different variances in the Indian population, and numerous disease-causing mutations are frequently magnified among certain of these groups. In February 2024, the Department of Biotechnology (DBT) declared the final conclusion of the "10,000 genomes" initiative, which aimed to establish an Indian whole-genome sequencing reference database.

Recent Developments in the Sequencing Market

  • In April 2024, the first all-in-one verified genetic stability test of its kind was released by Merck, a renowned science and technology business. The AptegraTM CHO, genetic stability assay, uses bioinformatics and whole genome sequencing to speed up clients' biosafety testing and, therefore, their transition to commercial production.
  • In March 2024, the next-generation genetic testing and analysis firm, Nucleus Genomics, announced the release of its DNA analysis solution, enabling everyone to benefit from customized treatment. Pre-orders for Nucleus's superior clinical-grade whole-genome sequencing (WGS) service, which involves reading and analyzing a customer's complete DNA collection, will also be available. In the summer, these more thorough WGS findings will start to become accessible. Members of Nucleus' platform will get access to additional features, sickness reports, and, in due course, reports for physical attributes like height and muscular strength for a $39 annual membership cost. The $399 30x WGS kit is required.
  • In June 2023, the new PrimateAI-3D artificial intelligence (AI) algorithm, which predicts disease-causing genetic abnormalities in patients with previously unheard-of precision, was unveiled today by Illumina Inc., a pioneer in the world of DNA sequencing and array-based technologies. The training and application of the algorithm to half a million genomes in the UK Biobank cohort are described in two publications that are published in the June 2 edition of Science. Additionally, two supporting publications on the monkey evolution study that influenced the creation of PrimateAI-3D were released in the journal.

Segments Covered in Sequencing Market Report

By Product & Services

  • Platform
    • 1st Generation of Sequencing Device
    • 2nd Generation of Sequencing Device
    • 3rd Generation of Sequencing Device
  • Consumables
    • Kits
      • DNA Library Preparation
      • RNA Library Preparation
      • Target Enrichment Library Quantification
      • Purification & Quality Control
      • Others
    • Reagents
      • Sample Prep
      • Library Preparation and Amplification
      • Sequencing
    • Accessories
      • Collection Tubes
      • Plates
      • Others
  • Services
  • Software

By Workflow

  • Pre-Sequencing
  • Sequencing
  • Data Analysis

By Application

  • Oncology
    • Diagnostics and Screening
    • Oncology Screening
      • Sporadic Cancer
      • Inherited Cancer
    • Companion Diagnostics
    • Other Diagnostics
    • Research Studies
  • Clinical Investigation
    • Infectious Diseases
    • Inherited Diseases
    • Idiopathic Diseases
    • Non-Communicable/Other Diseases
  • Reproductive Health
    • NIPT
      • Aneuploidy
      • Microdeletions
      • PGT
      • Newborn Genetic Screening
      • Single Gene Analysis
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Agrigenomics & Forensics
  • Consumer Genomics

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

Purification of genetic material or protein, reading the sequencing, data analysis and comparison with other sequences.

Whole-exome and targeted sequencing, whole-genome sequencing, RNA sequencing and methylation sequencing.

Map-based method, BAC-based method, hierarchical method, clone-by-clone method.

National Institute of Health, the National Cancer Institute, The World Economic Forum and the World Health Organization.